Damora Secures $535M Runway, Targets DMR-001 IND Submission by Mid-2026
Damora Therapeutics held $535 million in cash as of February 28, 2026, following $285 million private and $316 million public financings, funding operations into Phase 3 for lead candidate DMR-001. The company expects IND or CTA submission for DMR-001 by mid-2026 and initial proof-of-concept data in mid-2027.
1. Financial Position and Fundraising
Damora reported $257.6 million in cash at year-end 2025 and raised $285 million in a private financing plus $316 million in a February 2026 public offering, bringing total cash and equivalents to $535 million as of February 28, 2026. This funding is expected to support operations through Phase 3 development of lead program DMR-001.
2. Pipeline Developments and Upcoming Milestones
The company plans to submit an IND or CTA for DMR-001 in mutCALR-driven essential thrombocythemia and myelofibrosis by mid-2026, with two clinical proof-of-concept datasets anticipated beginning mid-2027. Additional IND or CTA submissions are slated for DMR-002 in the second half of 2026 and DMR-003 in 2027.
3. Corporate Restructuring and Leadership
In November 2025, Damora acquired three mutant calreticulin-targeted programs, including DMR-001, DMR-002 and DMR-003. The company strengthened its leadership with Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes, M.D. as Chief Medical Officer, and completed a name change and Nasdaq listing under the ticker DMRA in March 2026.
4. Full-Year 2025 Financial Results
Research and development expenses rose to $26.9 million from $6.4 million due to increased preclinical and clinical activities and warrant-related costs. General and administrative expenses decreased to $9.7 million from $10.5 million, while net loss widened to $209.8 million from $21.4 million, driven by $174.3 million of in-process R&D costs from the acquisition.